Last reviewed · How we verify
NCT05571956
Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples
NA trial testing Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group in Pancreas Adenocarcinoma in 50 participants. Status unknown.
28 February 2024
Quick facts
| Lead sponsor | Ajou University School of Medicine |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 50 |
| Start date | 1 July 2020 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group
Conditions studied
- Pancreas Adenocarcinoma — all drugs for Pancreas Adenocarcinoma →
Sponsor
Ajou University School of Medicine
Who can join
20 and older, any sex, with Pancreas Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Organoid has emerged as the novel platform for preclinical anticancer drug testing in pancreatic ductal adenocarcinoma (PDA). However, most organoid models are not reconstituted with a tumor microenvironment. This study aimed to simultaneously establish PDA organoids and cancer-associated fibroblasts (CAFs) using endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) samples.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.
Pei L, Liu Y, Liu L, Gao S, et al · · 2023 · cited 170× · PMID 36759842 · DOI 10.1186/s12943-023-01731-z -
Organoids: The current status and biomedical applications.
Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274 -
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy.
Taurin S, Alzahrani R, Aloraibi S, Ashi L, et al · · 2025 · cited 15× · PMID 39622151 · DOI 10.1016/j.tranon.2024.102226 -
Organoid-based precision medicine in pancreatic cancer.
Beutel AK, Ekizce M, Ettrich TJ, Seufferlein T, et al · · 2025 · cited 9× · PMID 39540683 · DOI 10.1002/ueg2.12701 -
Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities.
Wang M, Zhao Y, Xu K, Liu C, et al · · 2025 · cited 4× · PMID 40534854 · DOI 10.3389/fimmu.2025.1617968 -
Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research.
Yan S, He Y, Zhu Y, Ye W, et al · · 2024 · cited 4× · PMID 38638528 · DOI 10.3389/fcell.2024.1384450 -
Optogenetically Activatable MLKL as a Standalone Functional Module for Necroptosis and Therapeutic Applications in Antitumoral Immunity.
Jeong DH, Kim S, Park HH, Woo KJ, et al · · 2025 · cited 3× · PMID 39921454 · DOI 10.1002/advs.202412393 -
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.
Tsukamoto Y, Hirashita Y, Shibata T, Fumoto S, et al · · 2023 · cited 3× · PMID 37627132 · DOI 10.3390/cancers15164104
Verify or expand the search:
- PubMed search for NCT05571956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreas Adenocarcinoma
Currently open trials in the same condition.
- NCT07043270 — 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC · Phase 2 · recruiting
- NCT07262957 — Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Inc · Phase 4 · recruiting
- NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
- NCT07022015 — Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy · NA · recruiting
- NCT06497777 — The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of · recruiting
Other Ajou University School of Medicine trials
Trials by the same sponsor.
- NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
- NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
- NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
- NCT05751603 — Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex · NA · not yet recruiting
- NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05571956 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
- Last refreshed: 10 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05571956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing